The Type II Glycoengineered Anti-CD20 Antibody MIL62 or Cyclosporine in Chinese Primary Membranous Nephropathy: Updated Results of an Ongoing, Multicenter, Randomized, Open-Label Phase 1b/2 Trial

Journal of the American Society of Nephrology(2023)

引用 0|浏览2
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要